Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.52 |
| ▸ | HTR1A | P08908 | 9/20 | 0.41 |
| ▸ | HTR2A | P28223 | 9/20 | 0.41 |
| ▸ | HTR7 | P34969 | 9/20 | 0.41 |
| ▸ | HTR6 | P50406 | 9/20 | 0.41 |
| ▸ | BACE1 | P56817 | 3/20 | 0.40 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20066170 | 0.85 | OPRM1 (0.58) | OPRM1OPRL1OPRK1HTR1AHTR2A | |
| SCHEMBL20066072 | 0.83 | OPRM1 (0.44) | OPRM1OPRL1OPRK1HTR1ABACE1 | |
| SCHEMBL29709409 | 0.83 | OPRM1 (0.44) | OPRM1OPRL1OPRK1HTR1ABACE1 | |
| SCHEMBL20073897 | 0.82 | DRD2 (0.47) | OPRM1OPRL1OPRK1 | |
| SCHEMBL23798683 | 0.81 | OPRL1 (0.59) | OPRM1OPRL1OPRK1HTR1AHTR2A | |
| SCHEMBL23798604 | 0.81 | OPRM1 (0.47) | OPRM1OPRL1OPRK1HTR1AHTR2A | |
| SCHEMBL23799177 | 0.80 | OPRL1 (0.61) | OPRM1OPRL1OPRK1HTR1AHTR2A | |
| SCHEMBL23778253 | 0.78 | OPRM1 (0.46) | OPRM1OPRL1OPRK1HTR1AHTR2A | |
| SCHEMBL23798701 | 0.77 | OPRM1 (0.51) | OPRM1OPRL1OPRK1HTR1AHTR2A | |
| Trifluoroacetic Acid SCHEMBL23778426 | 0.77 | OPRM1 (0.49) | OPRM1OPRL1OPRK1HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526207-B1 | HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. | HEPTARES THERAPEUTICS LTD (GB) | 2021-09-08 | — | — | EP | disclosed |
| WO-2018069732-A1 | HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-04-19 | — | — | WO | disclosed |